Urology FDA approvals of 2016 February 13, 2017 By Urology Times Staff Urology-related FDA approvals from 2016 encompassed drugs and devices for prostate cancer, renal cell carcinoma, bladder cancer, stone disease, and more. Lung cancer drug approved October 24, 2016 By Christine Blank Soon after FDA granted accelerated approval for atezolizumab (Tecentriq, Genentech) to treat bladder cancer, the agency okayed the drug to treat metastatic non-small cell lung cancer (NSCLC). PD-L1 inhibitor shows promise as first-line therapy A recently approved treatment for urothelial carcinoma provides durable responses when used as first-line treatment in patients who are ineligible for cisplatin-based therapy, according to a recent study. New Products: FDA approves combination regimen to treat advanced RCC July 20, 2016 By Ben Schwartz Other products discussed in this roundup include a smart-mobile connected ultrasound device, treatments for RCC, and more. Bladder Cancer: Androgen receptor activation a potential therapeutic target July 19, 2016 By Richard R. Kerr Multiple studies on exosomes, data from the IMvigor 210 trial of atezolizumab (TECENTRIQ), and research on prehabilitation for cystectomy were among the highlights in bladder cancer from the 2016 AUA annual meeting. How biomarkers can personalize cancer immunotherapy June 07, 2016 By Bryant Furlow ASCO 2016 presenters share how combination therapies and biomarkers can better identify which tumors are likely to succumb to particular immunotherapies What anti-PD-L1 immunotherapy approval means for urology June 06, 2016 By Lisette Hilton Urologist Peter Black, MD, discusses the recent FDA approval of atezolizumab (TECENTRIQ) for the most common form of bladder cancer as well as a complementary diagnostic test. Why new bladder cancer drug is novel May 27, 2016 By Christine Blank FDA recently granted accelerated approval for atezolizumab (Tecentriq, Genentech), the first drug for bladder cancer that utilizes the body’s immune system. The drug will be available by early June. Three drug trends impacting specialty pharmacy April 21, 2016 By Mari Edlin AMCP session, “Specialty Pharmaceutical in Development,” highlighted critical trends that healthcare executives should be watching Uro Pipeline: FDA grants priority review to advanced bladder Ca agent Also look for coverage of products in the pipeline for bladder pain syndrome/interstitial cystitis, prostate cancer, and male infertility.